Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study

Movement Disorders : Official Journal of the Movement Disorder Society
Jan C M ZijlmansFranck Durif

Abstract

We investigated whether administration of the catechol-O-methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations. In addition, the pharmacodynamics and safety of entacapone and apomorphine coadministration in these patients were examined. The study followed a three-sequence, three-period, crossover design. Patients were randomly assigned to one of three sequences that included single oral doses of entacapone 200 mg, entacapone 400 mg, and placebo in a predefined order. On 3 separate test days, study treatment was administered before apomorphine. The study evaluations (pharmacokinetics, tapping test, and dyskinesia evaluation [Abnormal Involuntary Movements Scale - AIMS]) were performed on these days. Furthermore, Unified Parkinson Disease Rating Scale (UPDRS) scores were evaluated at baseline and study end. Pharmacokinetic parameters for apomorphine (C(max), AUC, t(max), t(1/2)) were unchanged by the administration of entacapone, and changes in both the tapping test and AIMS score were similar with all treatments (entacapone 200 mg, entacapone 400 mg, and placebo). There was no significant dif...Continue Reading

References

Jan 1, 1978·Advances in Pharmacology and Chemotherapy·G Di Chiara, G L Gessa
Feb 1, 1990·Journal of Neurology, Neurosurgery, and Psychiatry·J P FrankelG M Stern
Aug 1, 1989·Annals of Neurology·S T GancherJ G Nutt
Nov 19, 1986·European Journal of Pharmacology·G BianchiS Garattini
Nov 1, 1971·Journal of Pharmaceutical Sciences·R V Smith, S P Sood
Jan 1, 1971·Journal of Pharmaceutical Sciences·P N Kaul, M W Conway
Feb 1, 1981·British Journal of Clinical Pharmacology·C D Marsden, M Schachter
Mar 4, 1995·BMJ : British Medical Journal·N Quinn
Jan 1, 1993·Fundamental & Clinical Pharmacology·E NicolleM Gavend
Jan 1, 1996·Journal of Neurology, Neurosurgery, and Psychiatry·H M Ruottinen, U K Rinne
Mar 26, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·F DurifY Agid

❮ Previous
Next ❯

Citations

May 24, 2005·Lancet Neurology·Anette Schrag
Sep 24, 2008·Handbook of Clinical Neurology·Claire Henchcliffe, M Flint Beal
Jan 13, 2018·Clinical Drug Investigation·Manon AuffretMarc Vérin
Sep 26, 2006·Journal of Psychiatric Practice·Sheldon H PreskornDavid Flockhart

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.